

EVALUATION OF THE USE, ADHERENCE AND TOLERANCE OF 0.03% TACROLIMUS EYE DROPS

Varela-Rey I^{1*}, González-Barcia M¹, García-Quintanilla L¹, Castro-Balado A¹, Busto-Iglesias M¹, Zarra-Ferro I¹, Fernández-Ferreiro A¹
¹ Clinical University Hospital of Santiago de Compostela, Hospital Pharmacy Department, Santiago de Compostela, Galicia, Spain
*iria.varela.rey@sergas.es

BACKGROUND AND IMPORTANCE:

Tacrolimus is a widely used immunosuppressant in many ophthalmic diseases. Its mechanism of action is the inhibition of calcineurin phosphatases, which inhibits the first phase of T-cell activation, which leads to a decrease in inflammatory activity. In Spain, no eye drops are commercialized, so its formulation as a pharmaceutical compounding in Hospital Pharmacy services is necessary.

AIM AND OBJECTIVES:


To evaluate the use, adherence and tolerance of 0.03% tacrolimus eye drops pharmaceutical compounding.

MATERIALS AND METHODS:

- ✓ Retrospective observational study.
- ✓ January-2017 to March-2020.
- ✓ Patients treated with 0.03% tacrolimus eye drops.

Recording:

- ❖ Demographic data: sex and age.
- ❖ Clinical data: pathology, duration, adherence and tolerance.



Adherence was measured by registration of dispensations, classifying as the highest level of adherence has no delay in dispensing, as well as by follow-up controls by Ophthalmology service.


RESULTS:

Demographic data:


54 patients
57.14% men
32.70±21.8 years

Mean duration:
1.8±1.0 years.


Adherence



Uses of 0,03% tacrolimus eye drops



Tolerance of 0,03% tacrolimus eye drops



CONCLUSION AND RELEVANCE:

Tacrolimus eye drops are used primarily for the treatment of vernal or atopic keratoconjunctivitis. Adherence was generally correct and the formulation has been well tolerated by most of the patients.